From: Economic evaluations of vaccines in Canada: a scoping review
Variable | Number of studies included | Percentage of total (n = 60) (%) |
---|---|---|
Source | ||
 Peer-reviewed | 55 | 91.7 |
 Grey-literature | 5 | 8.3 |
Year of publication | ||
 Before 1995 | 3 | 5.0 |
 1995–2004 | 17 | 28.3 |
 After 2005 | 40 | 66.7 |
Region | ||
 Canada | 35 | 58.3 |
 Atlantica | 2 | 3.3 |
 Quebec | 8 | 13.3 |
 Ontario | 6 | 10.0 |
 Manitoba | 1 | 1.7 |
 Saskatchewan | 0 | 0.0 |
 Alberta | 3 | 5.0 |
 British Columbia | 5 | 8.3 |
 Territoriesb | 0 | 0.0 |
Disease | ||
 Influenza | 10 | 16.7 |
 HPV | 9 | 15.0 |
 Pneumococcal | 9 | 15.0 |
 Pertussis | 5 | 8.3 |
 Meningoccocal A, C, Y or W135 | 5 | 8.3 |
 Hepatitis B | 5 | 5.0 |
 Varicella | 3 | 5.0 |
 Measles, mumps or rubella | 3 | 5.0 |
 Herpes zoster | 2 | 3.3 |
 Rotavirus | 2 | 3.3 |
 Rabies | 1 | 1.7 |
 Hepatitis A | 1 | 1.7 |
 Tetanus | 1 | 1.7 |
 Hepatitis C | 1 | 1.7 |
 Meningoccocal B | 1 | 1.7 |
 Group B Streptococcus | 1 | 1.7 |
 Escherichia coli | 1 | 1.7 |
Type of economic evaluation | ||
 Cost-utility | 37 | 50.0 |
 Cost-effectiveness | 30 | 40.5 |
 Cost-benefit | 7 | 9.5 |
Modelling type | ||
 Simple tree | 16 | 21.6 |
 Static cohort | 25 | 41.7 |
 Dynamic cohort | 7 | 11.7 |
 Individual-based | 5 | 8.3 |
 No modelling (e.g. RCT, simple calc.) | 7 | 11.7 |
Consideration herd immunity | ||
 Yes | 25 | 41.7 |
 No | 35 | 58.3 |
Time horizon | ||
 ≤1 year | 7 | 11.7 |
 >1–29 years | 14 | 23.3 |
 30–79 | 8 | 13.3 |
 80+ | 25 | 41.6 |
 Not stated | 6 | 10.0 |
Perspective | ||
 Individual/Familial | 4 | 6.7 |
 Healthcare pay | 35 | 58.3 |
 Public pay | 10 | 16.7 |
 Societal | 28 | 46.7 |
 Not stated | 8 | 13.3 |
Sensitivity analysis | ||
 Yes-deterministic | 53 | 88.3 |
 Yes-probabilistic | 23 | 38.3 |
 No | 5 | 8.3 |
Alternative/comparator | ||
 No vaccine | 40 | 66.7 |
 Different vaccine programs | 15 | 25 |
 Different types of vaccines | 16 | 26.7 |
Conflict of interest | ||
 Yes | 28 | 46.7 |
 No | 32 | 53.5 |